| Item Type | Name |
|
Concept
|
Nausea
|
|
Academic Article
|
Chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
|
|
Academic Article
|
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
|
|
Academic Article
|
Recent Advances in the Management of Chemotherapy-induced Nausea and Vomiting: A Case Study Compendium.
|
|
Academic Article
|
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
|
|
Academic Article
|
Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
New treatment options for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
|
|
Academic Article
|
Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.
|
|
Academic Article
|
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
|
|
Academic Article
|
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
|
|
Academic Article
|
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
|
|
Academic Article
|
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
|
|
Academic Article
|
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.
|
|
Academic Article
|
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
|
|
Academic Article
|
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
|
|
Academic Article
|
Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
|
|
Academic Article
|
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
|
|
Academic Article
|
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
|
|
Academic Article
|
Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
|
|
Academic Article
|
Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
|
|
Academic Article
|
Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
|
|
Academic Article
|
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
|
|
Academic Article
|
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
|
|
Academic Article
|
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
|
|
Academic Article
|
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
|
|
Academic Article
|
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
|
|
Academic Article
|
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
|
|
Academic Article
|
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
|
|
Academic Article
|
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
|
|
Academic Article
|
Oral ondansetron: a useful addition to the supportive care armamentarium?
|
|
Academic Article
|
Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
|
|
Academic Article
|
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
|
|
Academic Article
|
Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
|
|
Academic Article
|
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
|
|
Academic Article
|
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
|
|
Academic Article
|
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
|
|
Academic Article
|
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
|
|
Academic Article
|
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
|
|
Academic Article
|
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
|
|
Academic Article
|
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
|
|
Academic Article
|
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support.
|
|
Academic Article
|
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
|
|
Academic Article
|
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
|
|
Academic Article
|
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
|
|
Academic Article
|
Cannabinoids as antiemetics: everything that's old is new again.
|
|
Academic Article
|
Drug treatment of chemotherapy-induced delayed emesis.
|
|
Academic Article
|
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
|
|
Academic Article
|
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
|
|
Academic Article
|
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
|
|
Academic Article
|
Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
|
|
Academic Article
|
Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
|
|
Academic Article
|
Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.
|
|
Academic Article
|
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
|
|
Academic Article
|
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
|
|
Academic Article
|
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
|
|
Academic Article
|
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
|
|
Academic Article
|
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
|
|
Academic Article
|
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
|
|
Academic Article
|
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
|
|
Academic Article
|
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
|
|
Academic Article
|
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
|
|
Academic Article
|
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
|
|
Academic Article
|
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.
|
|
Academic Article
|
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
|
|
Academic Article
|
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
|
|
Academic Article
|
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
|
|
Academic Article
|
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
|
|
Academic Article
|
Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Antiemetic guidelines: creating a more practical treatment approach.
|